Soleno Therapeutics (SLNO) Cash & Current Investments (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Cash & Current Investments data on file, last reported at $255.6 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $255.6 million, down 11.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $255.6 million (down 11.84% YoY), and the FY2025 annual result was $305.5 million, up 4.82% from the prior year.
• Cash & Current Investments fell to $255.6 million in Q1 2026 per SLNO's latest filing, from $305.5 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $498.9 million in Q3 2025 and troughed at $7.9 million in Q1 2023.
• A 5-year average of $172.8 million and a median of $169.7 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 72.76% in 2023, then soared 1793.67% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $14.6 million in 2022, then surged by 1062.04% to $169.7 million in 2023, then surged by 71.76% to $291.4 million in 2024, then increased by 4.82% to $305.5 million in 2025, then fell by 16.33% to $255.6 million in 2026.
• Business Quant data shows SLNO's Cash & Current Investments at $255.6 million in Q1 2026, $305.5 million in Q4 2025, and $498.9 million in Q3 2025.